Among its three functional forms, HER2 protein overexpression and gene amplification have been reported in 6–35% and 10–20% of NSCLC cases, respectively, whereas HER2 genomic alterations are documented to occur in only 2–4% [2, 4]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.